Business
IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors
Canadian hospitals and health care providers have expressed strong interest in ProSense® as they seek minimally invasive treatments for breast and other
About this update from Icecure Medical Ltd.
[{"type":"text","content":"Canadian hospitals and health care providers have expressed strong interest in ProSense® as they seek minimally invasive treatments for breast and other tumors \nCAESAREA, Israel, July 25, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) (\"IceCure\" or the \"Company\"), developer of minimally-invasive cryoablation technology, the ProSense® System ( \"ProSense\") that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the submission of a regulatory filing with the Canadian governmental agency, Health Canada, for approval of IceCure's ProSense System and its cryoprobes for the treatment of numerous indications including:\nOncology – ablation of benign and malignant breast tumors as well as benign and malignant tumors of the lung, liver, and musculoskeletal system, and for palliative intervention;Urology – ablation of renal cell carcinoma;Thoracic surgery – ablation of cancerous lesions in the lung tissue; andOther indications and for general surgery.The ProSense System currently has regulatory approval for various indications in 14 countries, including in the U.S. and Europe.\nAccording to statistics from the Canadian Cancer Society, an estimated 28,600 women will be diagnosed with breast cancer in Canada in 2022, while an estimated 30,000 people will be diagnosed with lung cancer. Furthermore, breast cancer is the most common cancer among Canadian women. About 1 in 8 women will be diagnosed with the disease in their lifetime.\n\"We have been contacted by multiple Canadian healthcare providers, including hospitals, with requests to purchase and implement ProSense for treating a range of indications, with malignant breast tumors being the most pressing need,\" stated IceCure CEO, Eyal Shamir. \"We believe demand is being driven by a combination of ProSense's rising prominence in the global market and health care providers discovering, over the past two years during the pandemic, that they needed minimally invasive solutions that can be administered in an outpatient setting outside of an operating room. The benefits of minimally invasive procedures have become clearer than ever, driving demand in a post-pandemic environment. We hope to receive Health Canada's approval, further expanding ProSense's global regulatory and commercial footprint.\" \nAbout IceCure Medical Ltd.\nI...